Screener / SEC EDGAR /CIK 0001356576 /10-K filed Mar 2, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care · Pharmaceuticals

Supernus, Inc. SUPN

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Mar 2, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

12.3% to -8.7% (-21.0 pts)

The MD&A has no sentence that names a cause for this change.

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-152.2%

“The decrease in Net earnings (loss) was primarily due to higher amortization of intangible assets, higher selling, general, and administrative expenses, and higher contingent consideration loss as a result of the acquisition of Sage in 2025, offset by higher revenues.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-72.5%

The MD&A has no sentence that names a cause for this change.

Revenue

Change, FY to Dec 31, 2025 vs Dec 31, 2024

+8.6%

“The provision for sales discounts increased from $69.5 million in 2024 to $73.0 million in 2025 primarily attributable to new product launched in 2025 and higher Qelbree sales in 2025 compared to 2024.”

Read it in the 10-K

“Royalty, licensing and other revenues increased by $15.3 million from $24.1 million in 2024 to $39.4 million in 2025, primarily due to an increase in licensing revenues related to the achievement of a regulatory milestone under our collaboration agreement with Shionogi.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +8.6%

    “The provision for sales discounts increased from $69.5 million in 2024 to $73.0 million in 2025 primarily attributable to new product launched in 2025 and higher Qelbree sales in 2025 compared to 2024.”

    Read it in the FY 2025 10-K

    “Royalty, licensing and other revenues increased by $15.3 million from $24.1 million in 2024 to $39.4 million in 2025, primarily due to an increase in licensing revenues related to the achievement of a regulatory milestone under our collaboration agreement with Shionogi.”

    Read it in the FY 2025 10-K
  • FY 2024 +8.9%

    “The provision for sales discounts increased from $65.9 million in 2023 to $69.5 million in 2024 primarily attributable to higher net product sales in 2024 compared to 2023.”

    Read it in the FY 2024 10-K

    “Royalty, licensing and other revenues decreased by $9.5 million from $33.6 million in 2023 to $24.1 million in 2024, primarily due to lower royalties on generic Trokendi XR due to the increased number of generic entrants.”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 -21.0 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +13.2 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Net income

2 of 2 years explained
  • FY 2025 -152.2%

    “The decrease in Net earnings (loss) was primarily due to higher amortization of intangible assets, higher selling, general, and administrative expenses, and higher contingent consideration loss as a result of the acquisition of Sage in 2025, offset by higher revenues.”

    Read it in the FY 2025 10-K
  • FY 2024 +5512.8%

    “The effective tax rate is impacted by benefits from research and development credits and capital losses that were mostly offset by an increase in the deferred tax asset valuation allowance for net operating losses and investments during the year.”

    Read it in the FY 2024 10-K

    “The increase in net earnings was primarily due to the higher revenues in 2024 from Qelbree and GOCOVRI and lower total costs and expenses in 2024, as well as no intangible asset impairment charge in fiscal year 2024.”

    Read it in the FY 2024 10-K

Cash from operations

0 of 2 years explained
  • FY 2025 -72.5%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +54.8%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SUPN/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.